A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)

PURPOSE: FOLFOXIRI plus bevacizumab is regarded as a first-line therapeutic option for selected patients with metastatic colorectal cancer (mCRC). Our aim was to assess the efficacy and safety of induction treatment with FOLFOXIRI plus bevacizumab in patients with untreated mCRC harboring UGT1A1 wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Katsunori, Yamada, Takeshi, Nasu, Junichiro, Matsumoto, Toshihiko, Yuasa, Yasuhiro, Shiraishi, Takeshi, Nagano, Hiroaki, Moriyama, Ichiro, Fujiwara, Toshiyoshi, Miguchi, Masashi, Yoshida, Ryosuke, Nozaka, Kimiyasu, Tanioka, Hiroaki, Nagasaka, Takeshi, Kurisu, Yasuro, Kobayashi, Michiya, Tsuchihashi, Kenji, Inukai, Michio, Kikuchi, Takashi, Nishina, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819906/
https://www.ncbi.nlm.nih.gov/pubmed/33097971
http://dx.doi.org/10.1007/s10147-020-01811-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819906/
https://www.ncbi.nlm.nih.gov/pubmed/33097971
http://dx.doi.org/10.1007/s10147-020-01811-w

Ejemplares similares